

Vivir con VIH: comprender la experiencia de los pacientes y valorar la ciencia – Tweetorial #2

Referencias

Tweet 3

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Updated January 20, 2022. Accessed February 4, 2022. <https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines>

Tweet 4

Back D, Marzolini C. The challenge of HIV treatment in an era of polypharmacy. *J Int AIDS Soc.* 2020;23(2):e25449. doi:10.1002/jia2.25449

Edelman EJ, Rentsch CT, Justice AC. Polypharmacy in HIV: recent insights and future directions. *Curr Opin HIV AIDS.* 2020;15(2):126-133. doi:10.1097/COH.0000000000000608

Tweet 5

Back D, Marzolini C. The challenge of HIV treatment in an era of polypharmacy. *J Int AIDS Soc.* 2020;23(2):e25449. doi:10.1002/jia2.25449

Edelman EJ, Rentsch CT, Justice AC. Polypharmacy in HIV: recent insights and future directions. *Curr Opin HIV AIDS.* 2020;15(2):126-133. doi:10.1097/COH.0000000000000608

Tweet 7

Knechten H, Stephan C, Waizmann M, et al. Patient-reported outcomes (PROs) after 1 year of routine clinical practice with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): The BICSTaR cohort. Abstract P053. Presented at: HIV Glasgow; October 23-26 2020; Virtual. <https://www.hivglasgow.org/wp-content/uploads/2020/11/P053-van-Welzen.pdf>

Tweet 8

Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. *N Engl J Med.* 2020;382(12):1112-1123. doi:10.1056/NEJMoa1904398

Tweet 9

Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. *N Engl J Med*. 2020;382(12):1112-1123. doi:10.1056/NEJMoa1904398

Tweet 11

Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir + rilpivirine every 2 months: ATLAS-2M week 152 results. Poster H03. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 12-16 2022; Virtual. <https://www.croiconference.org/abstract/long-acting-cabotegravir-rilpivirine-every-2-months-atlas-2m-week-152-results/>

Tweet 12

Gupta S, Sims J, Brinson C, et al. Lenacapavir as part of a combination regimen in treatment naïve PWH: Week 54 results. Abstract 138. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 12-16 2022; Virtual. <https://www.croiconference.org/abstract/lenacapavir-as-part-of-a-combination-regimen-in-treatment-naive-pwh-week-54-results/>

Tweet 13

Gupta S, Sims J, Brinson C, et al. Lenacapavir as part of a combination regimen in treatment naïve PWH: Week 54 results. Abstract 138. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 12-16 2022; Virtual. <https://www.croiconference.org/abstract/lenacapavir-as-part-of-a-combination-regimen-in-treatment-naive-pwh-week-54-results/>

Tweet 14

Segal-Maurer S, DeJesus E, Stellbrink H-J, et al. Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. *N Engl J Med*. 2022;386(19):1793-1803. doi:10.1056/NEJMoa2115542

Glosario

ART, antiretroviral therapy
AE, adverse event
AIDS, acquired immunodeficiency syndrome
BIC, bictegravir
CAB, cabotegravir
CD, cluster of differentiation
FTC, emtricitabine
HIVTSQc, HIV Treatment Satisfaction Questionnaire – change
HIVTSQs, HIV Treatment Satisfaction Questionnaire – status
HIV, human immunodeficiency virus
HRQOL, health-related quality of life
HTE, heavily-treatment experienced
INSTI, integrase strand transfer inhibitor
IQR, interquartile range
ISR, injection site reaction
LEN, lenacapavir
LS, least squares
MDR, multidrug resistant
NNRTI, nonnucleoside reverse transcriptase inhibitor
OBR, optimized background regimen
PLWH, people living with HIV/AIDS
PI, protease inhibitor
PRO, patient-reported outcome
Q4W, once every four weeks
Q8W, once every eight weeks
QD, once a day
QOL, quality of life
RNA, ribonucleic acid
RPV, rilpivirine
SF-36, 36-item Short Form Health Survey
SC, subcutaneous
TAF, tenofovir alafenamide
TE, treatment experienced
w/, with